In vitro/in vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans

Biopharmaceutics and Drug Disposition

Volumn 22, Issue 2, 2001, Pages 53-71

  Hirota, Noriko ^a   Ito, Kiyomi ^b   Iwatsubo, Takafumi ^c   Green, Carol E ^d   Tyson, Charles A ^d   Shimada, Noriaki ^e   Suzuki, Hiroshi ^a   Sugiyama, Yuichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b KITASATO UNIVERSITY   (Japan)

^c INSTITUTE FOR DEVELOPMENTAL RESEARCH   (Japan)

^d SRI INTERNATIONAL   (United States)

^e DAIICHI PURE CHEMICALS CO LTD   (Japan)

Author keywords

Alprazolam; CYP3A4; CYP3A5; In vitro in vivo scaling; Metabolism

Indexed keywords

ALPRAZOLAM; CIMETIDINE; CYTOCHROME B5; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; ISOENZYME; KETOCONAZOLE; RECOMBINANT ENZYME;

ACTIVE TRANSPORT; ADULT; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISPOSITION; DRUG HYDROXYLATION; DRUG INHIBITION; DRUG METABOLISM; DRUG STRUCTURE; DRUG TRANSPORT; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INSECT CELL; INTESTINE CELL; LIVER MICROSOME METABOLISM; MALE; MEDICAL LITERATURE; METABOLIC CLEARANCE RATE; PROTEIN CONTENT; PROTEIN EXPRESSION;

ADULT; ALPRAZOLAM; ANTI-ANXIETY AGENTS; AREA UNDER CURVE; CIMETIDINE; CYTOCHROME P-450 ENZYME SYSTEM; CYTOCHROMES B5; FEMALE; HUMANS; INTESTINES; KETOCONAZOLE; MALE; MICROSOMES, LIVER; MIDDLE AGED; MIXED FUNCTION OXYGENASES; RECOMBINANT PROTEINS;

EID: 0035663301     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.261     Document Type: Article

References (53)

1. Role of pharmacokinetics and metabolism in drug discovery and development
2. Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics
3. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data
4. Quantitative prediction of in vivo drug clearance from in vitro data on metabolism, together with binding and transport
5. In vitro and in vivo drug interactions involving human CYP3A
6. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
7. 5 in the oxidation of testosterone and nifedipine by recombinant cytochrome P450 3A4 and by human liver microsomes
8. Cytochrome P450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver
9. Identification of a polymorphically expressed member of the human cytochrome P-450III family
10. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3)
11. Urinary screening for alprazolam and its major metabolites by the Abbot ADx and TDx analyzers with confirmation by GC/MS
12. Regioselective biotransformation of midazolam by members of the human Cytochrome P450 3A (CYP3A) subfamily
13. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism
14. Prediction of pharmacokinetic alterations caused by drug-drug interactions: Metabolic interaction in the liver
15. Ketoconazole inhibition of triazolam and alprazolam clearance: Differential kinetic and dynamic consequences
16. Pharmacokinetic consequences of long term coadministration of cimetidine and triazolobenzodiazepines, alprazolam and triazolam, in healthy subjects
17. Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam
18. 2 receptor antagonists, cimetidine and nizatidine, into isolated rat hepatocytes: Contribution of type I system
19. A pharmacokinetic analysis program (MULTI) for microcomputer
20. Interspecies correlation of plasma concentration history of methotrexate
21. Methotrexate pharmacokinetics
22. Computer simulation of sulfobromophthalein kinetics in the rat using flow-limited models with extrapolation to man
23. A dispersion model of hepatic elimination: 1. Formulation of the model and bolus considerations
24. 9.3. Animal scale-up
25. Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: Use of maximum unbound concentration of inhibitor at the inlet to the liver
26. Quantitative prediction of in vivo drug-drug interactions from in vitro data: Effects of active transport of inhibitors into the liver
27. Interaction of propoxyphene with diazepam, alprazolam and lorazepam
28. Alprazolam kinetics in the elderly. Relation to antipyrine disposition
29. Comparative single-dose kinetics and dynamics of lorazepam, alprazolam, prazepam, and placebo
30. Single- and multiple-dose pharmacokinetics of oral alprazolam in healthy smoking and nonsmoking men
31. Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration
32. Alprazolam pharmacokinetics in alcoholic liver disease
33. Pharmacokinetics and clinical effects of alprazolam following single and multiple oral doses in patients with panic disorder
34. Comparison of alprazolam plasma levels in normal Asian and Caucasian male volunteers
35. A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: In vivo evidence for the involvement of CYP3A4 in alprazolam metabolism
36. Abuse liability and clinical pharmacokinetics of alprazolam in alcoholic men
37. Alprazolam kinetics in patients with renal insufficiency
38. Alprazolam pharmacokinetics in women on low-dose oral contraceptives
39. Alprazolam in end-stage renal disease: I. Pharmacokinetics
40. Multiple dose pharmacokinetics of ketoconazole and their effects on antipyrine kinetics in man
41. Clinical pharmacokinetics of ketoconazole
42. Influence of food on the pharmacokinetics of ketoconazole
43. Pharmacokinetics of cimetidine after single doses and during continuous treatment
44. 14C]cimetidine in man
45. Pharmacokinetics and bioavailability of cimetidine in gastric and duodenal ulcer patients
46. Alprazolam metabolism in vitro: Studies of human, monkey, mouse, and rat liver microsomes
47. Inhibitors of alprazolam metabolism in vitro: Effect of serotonin-reuptake-inhibitor anti-depressants, ketoconazole and quinidine
48. Use of midazolam as a human cytochrome P-450 3A Probe: I. In vitro-in vivo correlations in liver transplant patients
49. Biotransformation of alprazolam by members of the human cytochrome P4503A subfamily
50. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism
51. Characterization of midazolam metabolism using human hepatic microsomal fractions and hepatocytes in suspension obtained by perfusing whole human livers
52. Reduction of 3′-azido-3′-deoxythymidine to 3′-amino-3′-deoxythymidine in human liver microsomes and its relationship to cytochrome P-450
53. Inhibition of human CYP3A catalyzed 1′-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine